VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE Amex: CVM) announced today that Dr. Eyal Talor, the Company’s Chief Scientific Officer, will be giving a featured presentation titled “Latest Clinical Results using Multikine® Immunotherapy for Cancer” today at 3:05 pm London time at the “Targeted Cancer Therapies” conference in London, UK. The presentation will highlight Multikine’s role as a potential treatment for head and neck cancer, and will include a discussion of Phase II clinical results and details on the Company’s upcoming Phase III pivotal study.
